Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1995-05-31
1996-11-05
Budens, Robert D.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
4241531, 4241731, 435 7021, 4351722, 43524027, 5303871, 53038822, 5303887, 53038885, 5303913, 5303896, A61K 39395, C07K 1628, C12P 2108, C12N 520
Patent
active
055715133
ABSTRACT:
Anti-gp130 monoclonal antibodies (Mabs) obtained from hybridomas designated 4B11 and 2H4 are effective in the inhibition of the acute phase response on hepatoma cells and prevent the IL-6-induced growth inhibition of A375 cells in vitro. Administration of the antibodies to dogs showed that 2H4 is a potent in vivo inhibitor of the IL-6-induced acute phase response, abrogating IL-6-mediated-increments in fibrinogen, C-reactive protein and the platelet count. Antibodies may be used in methods for measuring soluble gp130 and in therapeutic treatments. The 2H4 antibody may be used in inhibiting in vivo the function of gp130 or cellular factors dependent on gp130 for cellular transduction.
REFERENCES:
Nishimoto et al. (1994) J. Exp. Mad. 179 1343-1347.
Tamura et al. (1993) Proc. Natl. Acad. Sci USA 90 11924-11928.
Yasukawa et al. (1992) Immunol. Letters 31 123-130.
Hibi et al. (1990) Cell 63 1149-1157.
Galfre (1981). Methods in Enzymology 73 1-46.
Mackiewicz et al., "Complex of Soluble Human IL-6-Receptor/IL-6 Up-Regulates Expression of Acute-Phase Proteins", The Journal of Immunology, vol. 149, 2021-2027, Sep. 15, 1992.
Taga et al., "Functional Inhibition of Hematopoietic and Neurotrophic Cytokines by Blocking the Interleukin 6 Signal Transducer gp130", Proc. Natl. Acad. Sci. USA, vol. 89, 10998-11001, Nov. 1992.
Narazaki et al., "Soluble Forms of the Interleukin-6 Signal-Transducing Receptor Component gp130 in Human Serum Possessing a Potential to Inhibit Signals Through Membrane-Anchored gp130", Blood, vol. 82, No. 4, 1120-1126, Aug. 15, 1992.
Wendling et al., "Treatment of Severe Rheumatoid Arthritis By Anti-Interleukin 6 Monoclonal Antibody", The Journal of Rheumatology, 20:259-262, 1993.
Saito et al., "Preparation of Monoclonal Antibodies Against the IL-6 Signal Transducer, gp130, That Can Inhibit IL-6-mediated Functions", Journal of Immunological Methods, 163:217-223, 1993.
Budens Robert D.
Reeves Julie E.
The Board of Regents of the University of Oklahoma
LandOfFree
Anti-gp130 monoclonal antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-gp130 monoclonal antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-gp130 monoclonal antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2013193